|Bid||39.10 x 1300|
|Ask||39.13 x 1800|
|Day's Range||38.52 - 39.18|
|52 Week Range||34.35 - 46.62|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||11.65|
|Earnings Date||Apr 21, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.18|
The new coronavirus that was first identified late last year in Wuhan, China, is a dominant theme in the earnings releases and conference calls of S&P 500 companies as investors press for answers on how it will impact their business.
Healthcare, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The healthcare sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Some of the largest health care stocks in the world include Johnson & Johnson (JNJ) and Pfizer, Inc. (PFE).
The yearly results for Boston Scientific Corporation (NYSE:BSX) were released last week, making it a good time to...
The spreading coronavirus epidemic will disrupt supply chains and reduce surgeries. So far, the costs don’t look all that threatening. But as the crisis grows, the effects will be felt across the global economy.
There are now 28,256 confirmed coronavirus cases in 25 countries and at least 565 deaths, according to the latest figures from the World Health Organization (WHO).
Shares of BSX stock slipped a fraction Wednesday after medical technology company Boston Scientific topped fourth-quarter adjusted profit expectations, though sales came in light.
While women make up one-quarter of leadership teams among the 25 largest publicly traded companies in Massachusetts, they represent just 4 percent of CEOs, according to a new report.
Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.
One of Massachusetts’ largest employers reported its best revenue figures in the last decade, but concerns about China appear to have dampened the news.
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an operational1 basis and 7.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP earnings of $3.996 billion or $2.83 per share (EPS), compared to GAAP earnings of $386 million or $0.27 per share a year ago and achieved adjusted earnings per share of $0.46 for the period, compared to $0.39 a year ago. Reported GAAP earnings include a significant net income tax benefit explained in the Use of Non-GAAP Financial Measures section below.
Boston Scientific shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
Today we are going to look at Boston Scientific Corporation (NYSE:BSX) to see whether it might be an attractive...
Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.